Star Therapeutics
Star Therapeutics raises $125M Series C at $650M valuation
Quick Facts
Star Therapeutics: Series C Funding Round
Star Therapeutics has successfully raised $125M in Series C funding, reaching a valuation of $650M.
Company Overview
Cell therapy platform for cancer treatment
Funding Details
The Series C round was led by RA Capital, with participation from Arch Venture Partners.
Company Information
- Headquarters: Cambridge, MA
- Founded: 2020
- Employees: 95+
- Category: Biotech
Investment
Star Therapeutics plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- RA Capital: Verified investor in Series C
- Arch Venture Partners: Verified investor in Series C
Key Investors
About the Author
Related Company Reports
Arthrosi Therapeutics raises $153M Series E at $800M valuation
Arthrosi Therapeutics raises $153M in Series E at $800M valuation. Developing next-generation gout treatment drug for chronic conditions...
HorizonStudio Raises $100M Growth to Transform Biotech
HorizonStudio has secured $100M Growth in funding to accelerate growth and innovation. Leading artificial intelligence infrastructure enabling scalable ML deployment for businesses...
StreamData Raises $15M Seed to Transform Biotech
StreamData has secured $15M Seed in funding to accelerate growth and innovation. Leading artificial intelligence infrastructure enabling scalable ML deployment for businesses...
